

ISSN 1365-3113
CODEN SYRREV

Volume 17 Number 1
February 2005

Systematic Reviews

in

Psychogeriatrics

Journal of the International Psychogeriatrics Society

www.systematicreviews.com




Journal of the International Psychogeriatrics Society
The Journal of the International Psychogeriatrics Society
is a peer-reviewed journal of research and practice
in the field of psychogeriatrics. It is published
quarterly by Taylor & Francis Ltd, London, UK.
The journal is required reading for all those
concerned with the care of the elderly.

Taylor & Francis Ltd
London, UK



Systematic Reviews in Pharmacy



[Online First](#)


[Archive](#)

[Aims and Scope](#)

[Abstracting & Indexing](#)

[Most Accessed Articles](#)

[Most Downloaded Articles](#)



[Google Scholar citation report](#)

Citations : 9175

[Systematic Reviews in Pharmacy received 9175 citations as per google scholar report](#)



Systematic Reviews Pharmacy

Editor

Verified email at sysrevpharm.org - [Homepage](#)

Pharmacy Pharmaceutical sciences pharmacology Biochemistry Biomedicine




GET MY OWN PROFILE

TITLE	CITED BY	YEAR
Nanoemulsion: A pharmaceutical review. P. Shah, D. Bhalodia, P. Shelat Systematic reviews in pharmacy 1 (1)	399	2010
Emulsion micro emulsion and nano emulsion: a review SN Kale, SL Deora Systematic Reviews in Pharmacy 8 (1): 39	279	2017
COVID-19 pandemic and home online learning system: Does it affect the quality of pharmacy school learning M. Suryaman, Y. Cahyona, D. Mulianayati, O. Eustani, P. Suryani, M. Fahlan, ... Systematic Reviews in Pharmacy 11 (5): 524-530	158	2020
Optimization of MSMEs empowerment in facing competition in the global market during the COVID-19 pandemic time A. Attandi, AS. Sarwani, H. Erlangga, AO. Siagian, A. Purwanto, AA. Effendi, ... Systematic Reviews in Pharmacy 11 (11): 1505-1515	107	2020
Biopharmaceutics classification system H. Chauda, C. Patal, I. Anand Systematic reviews in pharmacy 1 (1): 62	106	2010
University students online learning system during Covid-19 pandemic: Advantages, constraints and solutions NA. Fatoni, E. Nurkhyati, F. Nurdikawati, GP. Fidziati, S. Ardhag, ... Systematic Reviews in Pharmacy 11 (7): 570-576	93	2020
Coumarins: the antimicrobial agents YK. Al-Majedy, AAH. Kadhum, AA. Al-Amiry, AB. Mohamad Systematic Reviews in Pharmacy 8 (1): 62	91	2017
Ophthalmic drug delivery system: challenges and approaches P. Patel, D. Shashi, P. Shelat, A. Shukla Systematic Reviews in Pharmacy 1 (2): 113	85	2010

Cited by VIEW ALL

	All	Since 2017
Citations	9175	8587
h-index	36	35
h10-index	225	219



Systematic Reviews in Pharmacy peer review process verified at publons

Publons SEARCH

Systematic Reviews in Pharmacy

REVIEW POLICY ON PUBLONS

- Does not affect reviewer to be publicly displayed
- Only allows reviewers to display the journal they reviewed for

REVIEW

In accordance with Systematic Reviews in Pharmacy's editorial policy, review content is not publicly displayed on Publons.

INTEREST IN REVIEWING FOR THIS JOURNAL

For more information on the peer review process, please contact the editorial board at editorial@sysrevpharm.org.

THE HANDLING EDITOR ON PUBLONS (MANUSCRIPTS HANDLE)

[View Profile](#)

EDITORIAL BOARD MEMBERS ON PUBLONS

[View Profile](#)

SPONSORED BY

ADDITIONAL/CONTRIBUTING ENDORSEMENT

[ENDORSE THIS JOURNAL](#)

Indexed In

- > Genamics JournalSeek
- > JournalTOCs
- > China National Knowledge Infrastructure (CNKI)
- > Scimago
- > Ulrich's Periodicals Directory
- > EBSCO A-Z
- > Pollution Abstracts
- > OCLC- WorldCat
- > Proquest Summons
- > ROAD
- > CABI full text
- > SciLit - Scientific Literature
- > Publons
- > Google Scholar
- > J-Gate
- > Chemical Abstract
- > SHERPA ROMEO

Editorial Board

Editor-in-Chief

Tweets by @in_systematic

Dr. Ayad F. Alkaim

University of Babylon, College of Science for Women, Babylon, Scopus Author ID: 55255310600, Iraq

Systematic Reviews in Pharmacy

@in_systematic

Editorial Board

According to the new clinical data, 50-µg #boosterdose of mRNA-1273.214 had a potent neutralizing antibody response against the #OmicronVariant in all individuals, regardless of #immunity. [@in_systematic](#)

Prof. Dr. Miroslav Cernak, PhD

Professor, Department of Experimental and Translation Oncology

Croatian Institute for experimental and translation oncology, Zagreb, Croatia, Croatia

16h

Dr. Lucius, MBBS

Systematic Reviews in Pharmacy

General Practice

@in_systematic

Ludwig Maximilians University Munich, Germany

A phase 3 clinical trial of #brexpiprazole showed positive results in the treatment of agitation in patients with #Alzheimer dementia

Dr. Aygul Z. Ibatova

Department of Natural Sciences

Tyumen Industrial University, Scopus Author ID: 57191110632 <http://orcid.org/0000-0003-0565-8533>, Russia

View on Twitter

Dr Ahmad Faisal Ismail

Kulliyah of Dentistry

International Islamic University Malaysia, Kuantan Campus, 25200 Kuantan, Pahang, Scopus Author ID: 35388596700, Malaysia

Dr. Huiliang ZHAO, Ph.D

Guizhou Minzu University, Huaxi District, Guiyang, China

Dr. Mohd Armi Abu Samah

International Islamic University Malaysia, (IIUM) 25200 Kuantan Pahang

Dr. Baded ramji

Sri Lanka

Dr. Chris randea

South Africa

Dr. Yingwen ZHAO

Researcher of Guizhou Rural Economic and Social Development Research Institute, China

Dr. Li Zihan, Ph.D

University of Glasgow, UK

Gabriela Cioca

Faculty of Medicine, Pharmacology Department

Lucian Blaga University of Sibiu, Romania, Lucian Blaga street, no 2A, Sibiu, Romania

Dariusz Nowak

Municipal Hospital, Mickiewicza street no 12, 42-200 Czestochowa, Poland

Aleksandra Zyska

Faculty of Medicine, Department of Physiology

Opole University, Oleska street no 48, 45-052 Opole, Poland

Katarzyna Sznajder

Faculty of Medicine, Clinical Department of Diagnostic Imaging

Opole University, Oleska street no 48, 45-052 Opole, Poland

Jacek JAWIAK

Faculty of Medicine, Department of Family Medicine and Public Health

Opole University, Oleska street no 48, 45-052 Opole, Poland

Luciano Benedini

Universidad Nacional del Sur (National University of South-UNS), Bahía Blanca 8000, Argentina

Paula Messina

Departamento de Biología

Universidad Nacional del Sur (National University of South-UNS), Bioquímica y Farmacia, Bahía Blanca 8000, Argentina

Michael Walsh

Washington State University, College of Pharmacy and Pharmaceutical Sciences (CPPS), USA

Prof. Dr. Kittisak Jernsittiparsert

Henan University, China

Amel Dawod Kamel Gudia, PhD

Faculty of nursing
Cairo University, Egypt

Arif Nur Muhammad Ansori
Airlangga University, Scopus Author ID: 57195995342, <https://orcid.org/0000-0002-1279-3904>, Indonesia

Mohammed Nader Shalaby
Suez Canal University, Associate Professor of Biological Sciences and Sports Health, Egypt

Dr. Faten Abo-Aziza Mohamed, PhD
Associate Professor, Clinical Pathology and Stem Cell Research
National Research Centre, Manager of Veterinary Division Central Lab (605), 33 El-Beheos St, Dokki, Cairo, Egypt

Professor Asim Ahmed Elnour Ahmed
College of Pharmacy
Al-Ain University of Science and Technology, UAE

S. Parasuraman, M.Pharm., Ph.D
AIMST University, Malaysia

Ebenezer Wiafe, PhD
Pharmacy
University of Kwazulu-Natal, South Africa

[Submit Article](#)

[Login](#)

[Register](#)

Most Viewed Articles

Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli SRP. 2020; 11(1): 01-06 » doi: 10.5530/srp.2020.1.01

Psychometric properties of the World Health Organization Quality of life instrument, short form: Validity in the Vietnamese healthcare context Trung Quang Vo*, Bao Tran Thuy Tran, Ngan Thuy Nguyen, Trami ThiHuyen Nguyen, Thuy Phan Chung Tran SRP. 2020; 11(1): 14-22 » doi: 10.5530/srp.2019.1.3

A Review of Pharmacoeconomics: the key to "Healthcare for All" Hasamnis AA, Patil SS, Shaik Imam, Narendiran K SRP. 2019; 10(1): s40-s42 » doi: 10.5530/srp.2019.1s.21

Deuterium Depleted Water as an Adjuvant in Treatment of Cancer Anton Syroeshkin, Olga Levitskaya, Elena Uspenskaya, Tatiana Pleteneva, Daria Romaykina, Daria Ermakova SRP. 2019; 10(1): 112-117 » doi: 10.5530/srp.2019.1.19

Most Downloaded



Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaiti Mohd Kenali, Naimah Hasanah Mohd Fathil, Norbasyirah Bohari, Ahmad Faisal Ismail, Roszaman Ramli SRP. 2020; 11(1): 01-06 » doi: 10.5530/srp.2020.1.01

Manilkara zapota (L.) Royen Fruit Peel: A Phytochemical and Pharmacological Review Karle Pravin P, Dhawale Shashikant C SRP. 2019; 10(1): 11-14 » doi: 10.5530/srp.2019.1.2

Pharmacognostic and Phytopharmacological Overview on Bombax ceiba Pankaj Haribhau Chaudhary, Mukund Ganeshrao Tawar SRP. 2019; 10(1): 20-25 » doi: 10.5530/srp.2019.1.4



A Review of Pharmacoeconomics: the key to "Healthcare for All" Hasamnis AA, Patil SS, Shaik Imam, Narendiran K SRP. 2019; 10(1): s40-s42 » doi: 10.5530/srp.2019.1s.21

A Prospective Review on Phyto-Pharmacological Aspects of Andrographis paniculata Govindraj Akilandeswari, Arumugam Vijaya Anand, Palanisamy Sampathkumar, Puthamohan Vinayaga Moorthi, Basavaraju Preethi SRP. 2019; 10(1): 15-19 » doi: 10.5530/srp.2019.1.3



Copyright © 2022 Systematic Reviews in Pharmacy All Rights Reserved. Subject to change without notice from or liability to Systematic Reviews in Pharmacy. For best results, please use Internet Explorer or Google Chrome

- [Advertising Policy](#)
- [Author's Rights and Obligations](#)
- [Conflict of Interest Policy](#)
- [Digital Archiving & Preservation Policies](#)
- [Editorial Policies](#)
- [Peer Review Policy](#)
- [Editorial & Peer Review Process](#)
- [License Information](#)
- [Plagiarism Policy](#)
- [Privacy Policy](#)
- [Protection of Research Participants \(Statement On Human And Animal Rights\)](#)
- [Publishing Ethics](#)



[Online First](#)


[Archive](#)

[Aims and Scope](#)

[Abstracting & Indexing](#)

[Most Accessed Articles](#)

[Most Downloaded Articles](#)



[Google Scholar citation report](#)

Citations: 9175

Systematic Reviews in Pharmacy received 9175 citations as per google scholar report





Systematic Reviews Pharmacy

Editor

Verified email at sysrevpharma.org - [Homepage](#)


Pharmacy Pharmaceutical sciences pharmacology Biochemistry Biomedicine




GET MY OWN PROFILE

TITLE	CITED BY	YEAR
Nanoemulsion: A pharmaceutical review. P Shah, D Bhalodia, P Shelat Systematic reviews in pharmacy 1 (1)	399	2016
Emulsion micro emulsion and nano emulsion: a review SN Kale, SL Deore Systematic Reviews in Pharmacy 8 (1): 39	279	2017
COVID-19 pandemic and home online learning system: Does it affect the quality of pharmacy school learning M Suryaman, Y Cahyono, D Muhiansyah, O Bustani, P Suryani, M Fahien Systematic Reviews in Pharmacy 11 (3): 524-530	158	2020
Optimization of MSMEs empowerment in facing competition in the global market during the COVID-19 pandemic time A Afandi, AS Sarwani, H Erlangga, AO Siagian, A Purwanto, AA Effendy Systematic Reviews in Pharmacy 11 (1): 1506-1515	107	2020
Biopharmaceutics classification system H Chavda, C Patel, I Anand Systematic reviews in pharmacy 1 (1): 62	106	2016
University students online learning system during Covid-19 pandemic: Advantages, constraints and solutions NA Fatonia, E Nurkhatyic, E Nurdiafatid, GP Fidziah, S Adhag Systematic Reviews in Pharmacy 11 (7): 570-576	93	2020
Coumarins: the antimicrobial agents YK Al-Majedy, AAH Kadhum, AA Al-Amiry, AB Mohamad Systematic Reviews in Pharmacy 8 (1): 62	91	2017
Ophthalmic drug delivery system: challenges and approaches P Patel, D Shastri, P Shelat, A Shukla Systematic Reviews in Pharmacy 1 (2): 113	85	2016

Cited by	VIEW ALL	
	All	Since 2017
Citations	9175	8587
h-index	36	35
i10-index	225	219



Systematic Reviews in Pharmacy peer review process verified at publons



Indexed in

- > [Genamics JournalSeek](#)
- > [JournalTOCs](#)
- > [China National Knowledge Infrastructure \(CNKI\)](#)
- > [Scimagic](#)
- > [Ulrich's Periodicals Directory](#)
- > [EBSCO A-Z](#)
- > [Pollution Abstracts](#)
- > [OCLC-WorldCat](#)
- > [Proquest Summons](#)
- > [ROAD](#)
- > [CABI full text](#)
- > [SciLit - Scientific Literature](#)
- > [Publons](#)
- > [Google Scholar](#)
- > [J-Gate](#)
- > [Chemical Abstract](#)
- > [SHERPA ROMEO](#)



Review Article

TSH, FT4, and CD4 Profile in HIV/AIDS Patients Before and After Antiretroviral Fixed-Dose Combination Tenofovir, Lamivudine, Efavirenz Therapy

Dr. Jitthirakulki, Sany, Witsakorn, Usaman, Kiatit

SRP 2020, 11(3): 625 – 629

» Abstract » PDF [DOI: 10.31838/srp.2020.3.85](#)

Review Article

Factors affecting Job Satisfaction of Employees in Pharmaceutical Industry: A Case Study of Thailand

Dr. Wicharnat Sittisorn

SRP 2020, 11(3): 825 – 833

» Abstract » PDF [DOI: 10.55380/srp.2020.3.14](#)

Review Article

Identifying the Predictors of the Turnover Intentions: A Case of Thailand Pharmaceutical Companies

Dr. Pancha Nitiratt, Witsakorn, Kongsung, Jiraporn, Somying, Rattakorn, Kongsanti

SRP 2020, 11(3): 834 – 843

» Abstract » PDF [DOI: 10.55380/srp.2020.3.15](#)

Review Article

Role of High-Performance Oriented HR Practices towards the Citizenship Behaviour: A Case from Thai Pharmaceutical Sector

Dr. Paramee Saengnar, Niyom Saisaengde, Nigunvong, Kongsita, Rattakorn, Uayyacet

SRP 2020, 11(3): 844 – 853

» Abstract » PDF [DOI: 10.55380/srp.2020.3.16](#)

Review Article

Production of Laccase Enzyme by *Marasmius* sp. from the Bark of Cocoa Beans

Dr. Nida, Khamthipant, Witsakorn, Chai, Chai, Wanchuan, Rattakorn

SRP 2020, 11(3): 405 – 409

» Abstract » PDF [DOI: 10.55380/srp.2020.3.90](#)

Review Article

Application Of Non-Smoking Area Policy in Non Health Student Environments, Is That Effective?

Dr. Sr. Chuanthay, Rattakorn, Pong, Witsakorn, Rattakorn

SRP 2020, 11(3): 950 – 953

» Abstract » PDF [DOI: 10.31838/srp.2020.3.145](#)

Review Article

The Impact of HR Practices on the Services Innovation Behavior in the Pharmacy Sector of Thailand: Mediating Role of Organizational Commitment

Dr. Khoran, Sawanrat, Sittakorn, Saengphet, Nittichak, Jernsattijansert



1. Bhambhani S, et al. (2020) *Pharmacological Review of Herbal Products: A Systematic Review of Herbal Products*. *Journal of Pharmacy Research*. 11(3): 101-110. doi: 10.55555/srp.2020.11.3.101

2. Pharama S, et al. (2020) *Pharmacological Review of Herbal Products: A Systematic Review of Herbal Products*. *Journal of Pharmacy Research*. 11(3): 101-110. doi: 10.55555/srp.2020.11.3.101

3. A Review of Pharmacological Review of Herbal Products: A Systematic Review of Herbal Products. *Journal of Pharmacy Research*. 11(3): 101-110. doi: 10.55555/srp.2020.11.3.101

4. Prospective Review on Phyto-Pharmacological Aspects of *Anthraganthus paniculatus* (Santalaceae) Medicinal Plant. *Journal of Pharmacy Research*. 11(3): 101-110. doi: 10.55555/srp.2020.11.3.101

Copyright © 2022 Systematic Reviews in Pharmacy All Rights Reserved. Subject to change without notice from our liability to Systematic Reviews in Pharmacy.



Copyright © 2022 Systematic Reviews in Pharmacy All Rights Reserved. Subject to change without notice from our liability to Systematic Reviews in Pharmacy. For best results, please use Internet Explorer or Google Chrome.

POLICIES & JOURNAL LINKS

- [Advertising Policy](#)
- [Author's Rights and Obligations](#)
- [Conflict of Interest Policy](#)
- [Digital Archiving & Preservation Policies](#)
- [Editorial Policies](#)
- [Peer Review Policy](#)
- [Editorial & Peer Review Process](#)
- [License Information](#)
- [Plagiarism Policy](#)
- [Privacy Policy](#)
- [Protection of Research Participants \(Statement On Human and Animal Rights\)](#)
- [Publishing Ethics](#)
- [Corrections, Retractions & Expressions of Concern](#)
- [Self-Archiving Policies](#)
- [Statement of Informed Consent](#)
- [Terms of Use](#)



Review Article

The Intervention of Effective Playdough Activity on The Increase of Cognitive Development of Autistic Children

Dr. Afri Yusuf, Aulia Faridatul Umam, Ario Pulia Nurstij, Esti Yonitasari

SRP: 2020; 11(3): 200-207

» Abstract » PDF [DOI: 10.33888/srp.2020.3.108](#)

Review Article

Assessing the Performance of Heavy Cu²⁺ Metal Sorption by Immobilized Biosorbent in Fixed-bed Column Reactor Based on Breakthrough Curves

Dr. Astuti Wismanti, Nisichini Romantika Fachrud, Rosuliyanti Hidayatsetiawan, Dwiati Durnathani, Suparman

SRP: 2020; 11(3): 208-216

» Abstract » PDF [DOI: 10.33888/srp.2020.3.110](#)

Review Article

Effect of HRM Practices on Constructive Deviance in Pharmaceuticals Companies: Mediating by Ethical Climate

Dr. Walleerah Sidiqom

SRP: 2020; 11(3): 218-226

» Abstract » PDF [DOI: 10.33888/srp.2020.3.112](#)

Review Article

Characterization of Lactic Acid Bacteria and Determination of Antimicrobial Activity in Dadih from Air Dingin Alahan Panjang District, Solok Regency-West Sumatera

Dr. Harmaul Hanius, Yan Wilasari, Bambang Pusmarto, Erchang Purwati

SRP: 2020; 11(3): 228-236

[Salahin Article](#)

[Login](#)

[Register](#)

Most Viewed Articles:

Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaili Mohd Norzil, Nuraini Hanisah Mohd Farid, Nurhasyiah Sultan, Ahmad Fauzi Saad, Rozsawan Fawzi SRP: 2020; 11(3): 01-08 [doi: 10.33888/srp.2020.3.01](#)

Psychosocial Coping of Elderly Mental Health Organization Quality of Life Instrument, suitability in the Vietnamese healthcare context Trung Quang, V.C. Bao Nam, Trung Tran, Nguyen Thuy Nguyen, Tran Thi Myem Nguyen, Thuy Phuan Chung Tran SRP: 2020; 11(3): 14-22 [doi: 10.33888/srp.2020.3.03](#)

A Review of Pharmaceutical Services: The Key to "Wellness for All" Mesarika, N.A. Fitriyasa, Brian Akram, Nazrudin N SRP: 2020; 11(3): 341-347 [doi: 10.33888/srp.2020.3.21](#)

Chemical Characterization of Water-soluble Polyvinyl Alcohol Treatment of Cancer Antic-Byronshin, Chyul-Ho Shyya, Hwan-Deok Shyya, Heeun-Pyeong, Daein-Roan, Daein-Roan SRP: 2020; 11(3): 102-107 [doi: 10.33888/srp.2020.3.09](#)

Most Downloaded:

Dental Development between Assisted Reproductive Therapy (Art) and Natural Conceived Children: A Comparative Pilot Study Norzaili Mohd Norzil, Nuraini Hanisah Mohd Farid, Nurhasyiah Sultan, Ahmad Fauzi Saad, Rozsawan Fawzi SRP: 2020; 11(3): 01-08 [doi: 10.33888/srp.2020.3.01](#)



TSH, FT4, and CD4 Profile in HIV/AIDS Patients Before and After Antiretroviral Fixed-Dose Combination Tenofovir, Lamivudine, Efavirenz Therapy

Djati Susilo¹, Sony Wibisono^{2*}, Usman Hadi³

¹Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya 60131, Indonesia

²Endocrine and Metabolic Division, Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya 60131, Indonesia

³Tropical Disease and Infection Division, Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya 60131, Indonesia

Article History:

Submitted: 02.01.2020

Revised: 12.02.2020

Accepted: 15.03.2020

ABSTRACT

HIV infection can cause thyroid abnormality, and the use of Antiretroviral (ARV) can make it worse. The objective of this study was to identify the difference of thyroid profile level in HIV/AIDS before and after fixed-dose combination (FDC) therapy. This was a descriptive longitudinal observational study using one group pretest and posttest comparative design involving 20 samples. The subjects were all HIV/AIDS patients receiving ARV FDC but never received such therapy before. The mean age of the subjects was 32.9±9.19 years, with a range of 20-50 years. The majority of the subjects were males 15 (75%) and the most risk factor was vaginal sex as much as 11 subjects (55%). TSH and FT4 mean levels before therapy were 1.1 ± 0.22 μ U/ml FT4 and 1.15 ± 0.17 ng/dl, respectively and after receiving FDC ARV were of 2.34 ± 1.23 μ U/ml and 1.01 ± 0.14 ng/dl, respectively. There

were significant differences in TSH ($p = 0.000$), FT4 ($p = 0.012$), and CD4 ($p = 0.000$) in HIV/AIDS patients before and after receiving FDC ARV for 3 months. There was a significant difference in thyroid profile before and 3 months after received ARV FDC.

Keywords: HIV/AIDS, thyroid profile abnormality, antiretroviral

Correspondence:

Sony Wibisono

Endocrine and Metabolic Division, Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya 60131, Indonesia

E-mail: sonywibisono@yahoo.com

DOI: [10.31838/srp.2020.3.85](https://doi.org/10.31838/srp.2020.3.85)

©Advanced Scientific Research. All rights reserved.

INTRODUCTION

Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) has a high mortality rate and is the fourth leading cause of death in the world. Besides, HIV is rapidly growing, chronic, progressive and serious illness compared with other diseases.(1,2) However, the discovery of Highly Active Anti-Retroviral Therapy (HAART), or commonly called antiretroviral (ARV), is given to decrease the viral load in the blood. This helps to reduce the damage caused by HIV.(3,4) Almost 37.9 million people are living with HIV worldwide and it is estimated that 36.2 million of them are adults aged 15–49 years. Also, data in 2018 showed that there were 1.7 million new infections of HIV and around 770,000 people have died because of AIDS-related illnesses.(2) However, there are still some obstacles in the treatment of HIV patients who take ARVs. Also, HIV/AIDS prevention is very important and necessary.(5)

The incidence of thyroid abnormalities in HIV patients is about two to three times the general population. This condition is exacerbated by the use of ARVs. Various spectrums of thyroid abnormalities that often arise include overt hypothyroidism, subclinical hypothyroidism, isolated low Free Thyroxine (FT4)

and euthyroid sick syndrome (ESS). The detection of thyroid abnormalities is often difficult so that it increases the morbidity and mortality of HIV/AIDS patients.(6–8) Some studies recommended examining thyroid status in HIV patients to reduce morbidity and mortality, but until now there have been no official recommendations, both national and international, which suggest that data is still lacking and many aspects still need further investigation.(7,9)

The cause of the emergence of this thyroid disorder itself, the HIV/AIDS, can lead to a chronic inflammatory process

that affects the secretion of thyroid hormones, as similar with other infections.(10,11) and is exacerbated by the use of antiretroviral drugs through a disruption mechanism in the process of production and metabolism of thyroid hormone itself. Thyroid dysfunction in HIV patients can reduce the quality of life, increase morbidity and mortality.(12)

Thyroid hormones affect the body's immune system, where the process of maturation, differentiation, and activation is influenced by the levels of the thyroid hormones present. Besides, the incidence of cardiovascular disease due to hypothyroid and subclinical hypothyroidism is increasing, so thyroid profiles are important to evaluate.(13–15) This study aims to examine differences in thyroid profile level, represented by thyroid-stimulating hormone (TSH) and FT4, in HIV patients before and after 3 months of ARV therapy, especially those receiving the fixed-dose combination FDC (tenofovir, lamivudine, efavirenz) regimen as first-line treatment based on the 2015 Minister of Health Regulation.

METHODOLOGY

This study was a longitudinal observational study using one group pretest and posttest the design. The purpose of this study was to determine differences in TSH and FT4 levels before and 3 months after the administration FDC ARV. The study was conducted in the Outpatient Clinic of Infectious Disease Intensive Care, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo Hospital, Surabaya, Indonesia. Data were collected from May to September 2018.

The study population was patients diagnosed with HIV/AIDS who visited the Outpatient Clinic, Infectious Disease Intensive Care, Dr. Soetomo Hospital, Surabaya, Indonesia. Samples were patients diagnosed with

HIV/AIDS who visited the clinic from May to September 2018, who met the inclusion and exclusion criteria. Sampling in this study was conducted by consecutive sampling. If there were patients who met the inclusion and exclusion criteria in the population, the patients would be immediately included in the study. The number of the samples taken were total samples in the predetermined period.

The inclusion criteria in this study were HIV/AIDS patients who had not received ARV therapy in the Outpatient Clinic, Infectious Disease Intensive Care, Dr. Soetomo Hospital, Surabaya, Indonesia, between May - September 2018 according to Karnofsky performance status scale 80-100, patients aged 18-50 years, history taking can be performed on the patients, and the patients are willing to take part in the study by signing informed consent.

Exclusion criteria were patients undergoing ARV therapy, receiving anti-thyroid drugs and thyroid hormone agonists, consuming phenytoin, carbamazepine, amiodarone, ethionamide, PAS interferon, being critically ill or experiencing severe acute infection, having a history of routine alcohol use and smoked, had undergone thyroidectomy, had tuberculosis treatment with rifampicin regimen, had chronic diarrhea, was in a state of pregnancy, had liver disease/impaired liver function and chronic kidney disease, disobeying ARV treatment rules, having poor compliance and or loss to follow up, having adverse events that cause harm and/or hazard to life health and safety-related to ARV drugs used, and refusing to continue research for any reason.

Before the analysis, the normality of the data was tested. If the available data were normally distributed, a paired T-test was carried out and if the available data were abnormally distributed then the data were subjected to the Wilcoxon test. Paired T or Wilcoxon tests were used to compare TSH and FT4 levels before and 3 months after receiving FDC ARV therapy. The statistical test was regarded as significant if $p < 0.05$.

RESULTS

The general characteristics of the subjects were shown in Table 1. The mean age of the subjects was 32.9 ± 9.19 years, with the youngest being 20 years and the oldest 50 years. The majority of the subjects were males, 15 (75%), and the most risk factor was vaginal sex as much as 11 subjects (55%). Regarding the WHO clinical stage, subjects with clinical stage 1 were 5 subjects (25%), clinical stadium 2 were 13 subjects (65%), clinical-stage 3 were 2 (10%), and none of the subjects had clinical stage 4. Subjects with a CD4 cell count of less than 200 were 12 (60%), 4 subjects (20%) were in CD4 range of 200-349, 4 subjects (20%) were in CD4 range of 350-499 and none of the subjects had CD4 above 500.

TSH and FT4 levels were examined before and 3 months after receiving FDC ARV. Subjects' TSH and FT4 levels before receiving FDC ARV showed TSH mean levels of 1.1 ± 0.22 μ U/ml with normal data distribution. The FT4 level had mean value of 1.15 ± 0.17 ng/dl with normal data distribution. There was 1 subject (5%) with isolated low FT4 in the sample before receiving FDC ARV. TSH and FT4

levels of the subjects after receiving FDC ARV showed mean TSH of 2.34 ± 1.23 μ U/ml with normal data distribution. FT4 levels showed mean value of 1.01 ± 0.14 ng/dl with normal data distribution. There were 2 subjects (10%) with isolated low FT4, 2 subjects (10%) with subclinical hypothyroidism, and 1 subject (5%) with overt hypothyroidism (Table 2).

The difference of TSH before and three months after receiving FDC ARV treatment had normal data distribution, we used paired comparative T-test to analyze the difference. Comparative analysis between TSH and FT4 level in month 0 and month 3 in this study can be seen in Table 3. The table showed that there were significant differences in TSH, FT4, and CD4 with $p = 0.000$; $p = 0.012$; $p = 0.000$, respectively, in HIV/AIDS patients after receiving FDC ARV for 3 months.

DISCUSSION AND CONCLUSION

Findings from this study showed significant differences in TSH and FT4 levels before and after 3 months of treatment with FDC ARV. Thyroid profile abnormalities, such as overt hypothyroidism, subclinical hypothyroidism, and isolated low FT4, were found more in patients after ARV treatment. This indicates that thyroid profile abnormalities can occur in the first 3 months of consuming FDC ARV. There were significant differences in CD4 before and 3 months after receiving FDC ARV, where the mean post-FDC ARV treatment had a higher CD4 value. CD4 count was the most important biomarker of disease stage and progression in patients with an HIV infection.(16) Thyroid abnormalities were found more in CD4 >200, i.e. in patients after 3 months of ARV treatment.

In this study, the mean age of the subjects was in the range of 20-50 years. This is in accordance with statistical data from the Ministry of Health in 2017 that most individuals with HIV ranged in age from 25-49 years.(8) We limited the age in this study, because of the older the age, the higher the incidence of thyroid abnormalities. Besides, the number of individuals with HIV/AIDS in older age is also low. The majority of the subjects were males. Based on the data from the Ministry of Health in 2017, most individuals with HIV/AIDS were males with ratio male: female 2:1, probably because of the high risk of risky vaginal sex and anal sex, where the key group was the homosexual males with risky anal sex.(8,17)

The risk factor characteristics of this study were found with risky anal sex, and risky vaginal sex. None of our research subjects had risk factors for injecting drugs, because even in the world HIV/AIDS risk factors in the form of injecting drug use is declining, perhaps due to increased alertness among injecting drug users to HIV/AIDS infection.

Among 20 subjects in this study, most subjects were in clinical stage 2 and no subject with clinical stage 4. There were none of our study subjects with clinical stage 4 because our inclusion criteria were outpatients with good performance status. We also excluded the condition of patients with severe active infections, because it could become a confounding result of thyroid function examination. The clinical progression in HIV patients

receiving treatment is estimated by the different levels of viral load and CD4 count.(3)

Isolated low FT4 is one of the thyroid disorders quite often found in patients with HIV/AIDS. TSH levels before the starting of the treatment could be different between studies. This could result from several factors, including the method of TSH examination. Previous studies revealed that immunoassay examination for TSH measurements used different calibrations. Also, human TSH has different glycoforms, so that a different immunoassay examination may detect the TSH differently. This condition causes difficulty in the standardization of examinations and the presence of different results between each individual.(18) The results of the examination of thyroid profiles in the 3rd month could be regarded as quite significant, and, according to the theory we have discussed, there were significant thyroid abnormalities compared with the results before receiving FDC ARVs.(19,20)

In the post-treatment sample, subjects with CD4 levels <200 were decreased and those with CD4 >200 were increased. This increase in CD4 levels may indicate that the subjects were disciplined enough to take medication. The previous study obtained a correlation between CD4 and thyroid profile.(13) A study in India also found a correlation between CD4 and FT4. These findings differed from the findings of our study, where the number of subjects with CD4 <200 decreased after administration of ARV for three months and the population with CD4 levels >200 increased, where thyroid profile abnormalities were mainly obtained in patients with CD4 levels >200. There are remain a challenge to control the HIV epidemic in developing countries due to the financial burdens for people living with HIV in accessing and receiving HIV care.(3)

There were significant differences in thyroid profile and CD4 before and 3 months after receiving ARV FDC, but the etiology of thyroid disturbances cannot be explained, if its caused by ARV or HIV infection itself. Future studies need to include periodic physical examinations with the ultrasound of the thyroid gland to help establish the occurrence of side effects in the thyroid gland; exclude confounding factors such as direct infection of the thyroid gland, radiological mass in the thyroid gland, and thyroid peroxidase antibody examination to rule out other causes of increased TSH; and the use of better research methods, such as prospective cohort analysis, with longer periods and involving control groups.

ACKNOWLEDGMENT

The authors thank Poernomo Budi Setiawan, MD, the Head of the Department of Internal Medicine, Universitas Airlangga, to Prof. Agung Pranoto, MD, Ph.D., the Head of Endocrine and Metabolic Division of the Department of Internal Medicine for valuable advice for this research, and Misofa Rusli, MD, Head of the Intermediary and Infectious Disease Treatment Unit, Dr. Soetomo Hospital, Surabaya, and all the nursing staff.

REFERENCES

1. Ardianto A, Khairunisa SQ, Kotaki T, Witaningrum AM, Qushay M, Juniastuti J, et al. The Prevalence Of

- Human Immunodeficiency Virus-1 (Hiv-1) Subtypes And Transmission Method Among Hiv/Aids Infection Patient In Tulungagung, East Java Indonesia. *Indones J Trop Infect Dis*. 2015;5(5):124-8.
2. Latif AI, Irwan AM. Models and benefits of palliative care for the quality of life of people with hiv: A systematic review. *HIV Nurs [Internet]*. 2019;19(4):80-5. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078775535&partnerID=40&md5=d5961b0c3e15fb78c3e7d9418ca285a8>
3. Lubis R, Bulgiba AM. Anti-retroviral therapy of HIV infected patients. *J Heal Transl Med [Internet]*. 2014;17(1):18-22. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-84920691942&partnerID=40&md5=2e7e9f9a7509ce0e24e84959a14756c5>
4. Kembaren T. The role of drugs in HIV prevention. In: *IOP Conference Series Earth and Environmental Science*. 2018.
5. Toetik Koesbardiati, Khasih SE, Muz'adah S. Integrating The Roles Of Stakeholders In Preventing The Hiv/Aids Transmission In East Java, Indonesia. *Indones J Trop Infect Dis*. 2017;6(5):124-30.
6. Katsamathi C, Jongjoroenprasert W, Chailurkit L, Udomsubpayakul U, Kiertiburanakul S. Prevalence of thyroid dysfunction in Thai HIV-infected patients. *Curr HIV Res [Internet]*. 2006 Oct;4(4):463-7. Available from: <https://pubmed.ncbi.nlm.nih.gov/17073621>
7. Bongiovanni M, Adorni F, Casana M, Tordato F, Tincati C, Cicconi P, et al. Subclinical hypothyroidism in HIV-infected subjects. *J Antimicrob Chemother [Internet]*. 2006/09/01. 2006 Nov;58(5):1086-9. Available from: <https://pubmed.ncbi.nlm.nih.gov/16950823>
8. Restogi, P., Singhal, R., Sethi, A., Agarwal, A., Singh, V.K., Sethi, R. Assessment of the effect of periodontal treatment in patients with coronary artery disease : A pilot survey (2012) *Journal of Cardiovascular Disease Research*, 3 (2), pp. 124-127. DOI: 10.4103/0975-3583.95366
9. Indonesia Ministry of Health. *Infodatin AIDS*. Jakarta: Ministry of Health; 2017.
10. Collaboration H-C, Ray M, Logan R, Sterne JAC, Hernández-Díaz S, Robins JM, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. *AIDS [Internet]*. 2010 Jan 2;24(1):123-37. Available from: <https://pubmed.ncbi.nlm.nih.gov/19770621>
11. Uotari T, Miittahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. *Expert Opin Ther Targets*. 2015;19(12):1637-50.
12. Miittahussurur M, Yamaoka Y. Helicobacter pylori virulence genes and host genetic polymorphisms as risk factors for peptic ulcer disease. *Expert Rev*

Gastroenterol Hepatol. 2015;9(12):1535.

13. Sprinz E, Lazaretti RK, Kuhmmer R, Ribeiro JP. Dyslipidemia in HIV-infected individuals. *Brazilian J Infect Dis*. 2010;14(6):575-88.
14. Beltran S, Lescure F-X, Desaillyou R, Douadi Y, Smail A, El Esper I, et al. Increased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screening. *Clin Infect Dis* [Internet]. 2003/07/28. 2003 Aug 15;37(4):579-83. Available from: <https://pubmed.ncbi.nlm.nih.gov/12905143>
15. Mezosi E, Szabo J, Nagy E V, Borbely A, Varga E, Paragh G, et al. Nongenomic effect of thyroid hormone on free-radical production in human polymorphonuclear leukocytes. *J Endocrinol* [Internet]. 2005 Apr;185(1):121-9. Available from: <https://pubmed.ncbi.nlm.nih.gov/15817833>
16. Miyake S, Yamamura T. NKT cells and autoimmune diseases: unraveling the complexity. *Curr Top Microbiol Immunol* [Internet]. 2007;314:251-67. Available from: <https://pubmed.ncbi.nlm.nih.gov/17593664>
17. Lumbanraja SN, Siregar DS. Association between red blood cell indices and CD4 count in HIV-positive reproductive women. In: *IOP Conf Series: Earth and Environmental Science* [Internet]. Institute of Physics Publishing; 2018. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045672326&doi=10.1088%2F1755-1315%2F125%2F1%2F012027&partnerID=40&md5=f3d9f7b9374edf2337a3c2966a60e23d>
18. Davies SC, Madijid B, Pardohudoyo S, Wiraguna AAGP, Patten JH, Upadisari LP. Prevalence of sexually transmissible infections (STI) among male patients with STI in Denpasar and Makassar, Indonesia: Are symptoms of urethritis sufficient to guide syndromic treatment? *Sex Health* [Internet]. 2007;4(3):213-5. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548361877&doi=10.1071%2FSH07017&partnerID=40&md5=9fd34f1fa1fb85e29940634108e8d>
19. Saravanan P, Dayan CM. Thyroid autoantibodies. *Endocrinol Metab Clin North Am*. 2001;30(2):315-37.
20. Erhahie, Ernest Oghenesunwa, Chiswuba Paul, and . 2019. Edible Insects' bio-actives as anti-oxidants: Current status and perspectives. *Journal of Complementary Medicine Research*, 10 (2), 89-102. doi:10.5455/jcmr.20190130100319
21. Collazos J, Ibarra S, Mayo J. Thyroid hormones in HIV-infected patients in the highly active antiretroviral therapy era: evidence of an interrelation between the thyroid axis and the immune system. *AIDS* [Internet]. 2003 Mar 28;17(5):763-5. Available from: <https://pubmed.ncbi.nlm.nih.gov/12646804>
22. Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Solinas P, et al. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study. *Clin Endocrinol (Oxf)* [Internet]. 2006 Apr;64(4):375-83. Available from: <https://pubmed.ncbi.nlm.nih.gov/16584508>

Table 1. General characteristics of subjects

Characteristics	N (%)
Sex	
Male	15 (75%)
Female	5 (25%)
Age (years)	
Mean±SD	32.9±9.19
Median	20-50
Risk Factor	
Anal sex	9 (45%)
Vaginal sex	11 (55%)
Clinical Stage	
Stage 1	5 (25%)
Stage 2	13 (65%)
Stage 3	2 (10%)
Stage 4	0
CD4 levels	
<200	12 (60%)
200-349	4 (20%)
350-499	4 (20%)
>500	0

Table 2. Distribution of TSH, CD4, FT4, and abnormalities in samples, pre and post

TSH (mean)	FT4 (mean)	Abnormalities
------------	------------	---------------

Sample "pre"	1.1 ± 0.22 µIU/ml	1.15 ± 0.17 ng/dl	
CD4 <200			1 (5%) isolated low FT ₄
CD4 >200			(-)
Sample "post"	2.34 ± 1.23 µIU/ml	1.01 ± 0.14 ng/dl	
CD4 <200			(-)
CD4 >200			2 (10%) isolated low FT ₄ , 1 (5%) subclinical hypothyroid, 2 (10%) overt hypothyroid

Table 3. Results of comparative test of thyroid profile and CD₄, pre and post-test (paired sample test)

	Mean	Sig (2-tailed)
TSH pre	1.1 ± 0.22 µIU/ml	
TSH post	2.34 ± 1.23 µIU/ml	p = 0.000
FT ₄ pre	1.15 ± 0.17 ng/dl	
FT ₄ post	1.01 ± 0.14 ng/dl	p = 0.012
CD ₄ pre	196 ± 157.67	
CD ₄ post	331.6 ± 179.2	p = 0.000